However, the result has cemented GSK's view that dostarlimab can become the "backbone" of its immuno-oncology R&D programmes ... reporting that the phase 2/3 COSTAR trial of Jemperli with ...
Jazz Pharma has bolstered its pipeline of cancer drugs through a $1.3 billion licensing agreement with Werewolf Therapeutics that adds its first immuno-oncology candidate. The Dublin-based pharma ...
Bharat Immunological & Biologicals Corporation Ltd., incorporated in the year 1989, is a Small Cap company (having a market cap of Rs 109.89 Crore) operating in Pharmaceuticals sector. Bharat ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback